Abstract
Hepatitis G virus (HGV) and hepatitis C virus (HCV) infections may have role in introducing or complicating the clinical outcome in patients with thalassemia. In this study, the molecular and serological prevalence of HGV and HCV infections were evaluated in patients with thalassemia and compared with healthy controls. In a cross sectional study, the samples were collected from 86 patients with thalassemia and 100 healthy controls. The anti-HCV and HGV antibodies were evaluated by enzyme-linked immunosorbent assay (ELISA) methods. Also, the HGV and HCV viremia were analyzed in patients with thalassemia and controls by multiplex-nested-real time-polymerase chain reaction (RTPCR) protocol. Our results showed that the anti-E2-HGV and HCV antibodies were found in 16 of 86 and 18 of 86 of thalassemia patients and none of controls, respectively. HGV viremia was diagnosed in 13 of 86 of patients with thalassemia and in 1of 100 of controls. HCV-RNA was diagnosed in 12 of 86 and 6 of 100 of thalassemia and healthy controls, respectively. The diagnosis of significant higher prevalence of HGV and HCV in patients with thalassemia compared with controls in this region of Iran emphasized the importance of these lymphotropic viral hepatitis infections in pathogenesis and outcome of thalassemia patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
